High dose IV vitamin C treatment guidelines have just been published by the Shanghai Medical Association as a partial treatment for both mild and severe infections of COVID-19, providing vital lessons for the global response.

“As far as I know, this is the first and only official guideline of using vitamin C in something as serious as coronaviral outbreak, by any government” – Dr. Richard Cheng MD, PhD.

With a deepening understanding of COVID-19, Chinese medical experts have drawn upon both domestic and external learnings in the clinical treatment of the virus, accumulating invaluable expertise in the prevention and control of the disease.

Based on the continuous observation, optimization and refinement of COVID-19 treatment plans, consensus of an expert panel in China concedes that high dose IV vitamin C is indeed an effective part of a comprehensive medical treatment protocol that also involves other medical drugs and procedures.

The findings outlined in a detailed report have been published in The Chinese Journal of Infectious Diseases and by The Shanghai Medical Association (SMA) and is being shared globally in medical circles, including hospitals in northern Italy, who are searching for new treatments to help improve patients prognosis.

The report, written by a group of 30 medical doctors, known as The Shanghai Novel Coronavirus Disease Clinical Treatment Expert Team, has utilised their combined experience and observations to draw up a clinical treatment plan to support China and the rest of the world with the prevention of the progress of the disease, to improve treatment success rates and help reduce patient mortality rate.

The treatment recommendations contained in the guidelines are based on the observations of more than 300 infected patients being treated by doctors at The Second Affiliated Hospital of Xi’an Jiaotong University in China. The report outlines recommended IV vitamin C dosage guidelines for mild to severe and critically ill cases.

The Full Official Covid-19 Treatment Guidelines:

Read it here in The Chinese Journal of Infectious Diseases.
Read it here in The Shanghai Medical Association.

Dr. Richard Cheng Video Reports:

Dr. Cheng has been reporting on developments from Shanghai via YouTube videos.

View here Dr. Cheng speaking about the latest IV vitamin C clinical trials in China.

View here Dr. Cheng speaking about the new official IV vitamin C treatment guidelines.

Dr. Richard Cheng MD, PhD, an American/Chinese physician, one of the 30 experts, has been instrumental in facilitating at least three officially approved IV vitamin C clinical trials currently underway in Chinese hospitals.

Dr. Cheng says:

“Following a personal exchange with the principle investigator on the first officially approved IV vitamin C clinical trial in China, he told me the preliminary results are promising. That the high dose IV vitamin C protocol, shows significant progress”.

Press Interviews Available:

If you would like to interview any experts on this subject and learn about the science and clinical evidence surrounding high dose IV vitamin C and its role in helping support the immune system I can put you directly in touch with:


The SMA is the Shanghai branch of The Chinese Medical Association (CMA) the largest and oldest government recognised medical organization in China. It was established by a group of medical professionals in 1915 with an aim to uniting medical professionals, upholding medical ethics and advocating social integrity. It currently counts over 430,000 members and 82 specialty societies. It publishes over 70 medical journals (including the Chinese Medical Journal), as well as a medical bulletin and a medical education magazine. The CMA plays a leading and active role in the nation’s medical education, training and professional exchanges.

Chinese Journal of Clinical Infectious Diseases was established in 2008 and is published bimonthly in both Chinese and English. It is the official journal owned by Chinese Medical Association (CMA) and is published by the First Affiliated Hospital, College of Medicine, Zhejiang University. It reports advances and progress in infectious diseases, and is a peer reviewed medical journal for all doctors, researchers, and health workers in this area. The editorial board of the journal consists of well-known experts on infectious diseases and also the experts on paediatrics, gynaecology, respiratory diseases, urology, nephrology, neurology, gastroenterology and dermatology.

The Second Affiliated Hospital of Xi’an Jiaotong University in China is one of the first third level grade-A hospitals in China. It is a large-scale modern general hospital integrating medical treatment, medical education, scientific research and preventive health care and is directly under the National Health Commission and the Ministry of Education. Find more information about the hospital here

Clinical trial: There is a clinical trial underway at ZhiYong Peng, Zhongnan Hospital in Wuhan to see whether high dose IV vitamin C infusions can help improve the prognosis of patients with COVID-19, there are 140 participants and results will be shared in September 2020.
Find more information about the clinical trial here
Find more information about the hospital here


Source :- https://pttoday.co.uk/2020/03/13/should-the-nhs-be-stocking-up-on-iv-vitamin-c/

Leave a Reply

Your email address will not be published. Required fields are marked *